Medicine Man Technologies Acquisition Target, MedPharm, to Launch a Landmark Randomized Clinical Trial Taking Aim at Treating Alzheimer’s with Cannabis
MedPharm, the leader in cannabis research and formulation development, which has agreed to be acquired by Medicine Man Technologies (OTCQX: MDCL), will launch a landmark, double-blind, placebo controlled clinical trial in the first half of 2020 to explore how cannabis works for patients with Dementia and Alzheimer’s.
MedPharm will be exploring the action of a research-based, scientifically formulated compound containing cannabinoids and nootropic nutrients in patients diagnosed with Dementia and Alzheimer’s. The study will encompass patient surveys, memory tests, caregiver surveys, brain scans, and blood tests.
“MedPharm will investigate a proprietary compound that contains naturally derived cannabinoids and excipients that have been scientifically demonstrated to positively affect brain function, with the goal of helping us better understand and treat Alzheimer’s,” Dr. Tyrell Towle, MedPharm research scientist, says.
This article originally appeared on Businesswire, click here to read more.
High Tops is a proud vendor of MedPharm products!